Research programme: autoimmune disorders and transplant rejection - Bristol-Myers Squibb/GTC
Alternative Names: Autoimmune disorders and transplant rejection research programme: Bristol-Myers Squibb/GTCLatest Information Update: 21 Feb 2013
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; GTC Biotherapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
- 18 Jun 2002 Genzyme Transgenics Corporation is now called GTC Biotherapeutics
- 09 Dec 1999 Preclinical development for Autoimmune disorders in USA (Unknown route)